

YOUR INVITATION TO ATTEND:

GeneSight® in Clinical Practice

A MYRIAD GENETICS SPEAKER PRESENTATION

A clinical and scientific discussion focusing on the basics of pharmacogenomics and review of the GeneSight® Psychotropic report and clinical data. Q&A to follow.



PRESENTER

Bernardo Rojas, MD

Dr. Rojas has practiced Adult Medicine since 2011. He has a special interest in caring for the geriatric population, particularly those with chronic medical conditions. His goal is always communication first. That is followed by total patient involvement in simplifying medications and making lifestyle changes that work toward achieving a better quality of life. Dr. Rojas is very active in the senior living community which allows him to be in the unique position to manage his patients at many stages throughout the continuum of care. His medical training and personal experiences with healthcare, he has come to realize that practicing good medicine involves being a good educator, a good listener, and a patient advocate. A product of his community, Dr. Rojas resides in Oakland County with his wife and 11-year-old son.

DATE & TIME

Thursday, June 11, 2026
6:30pm

LOCATION

Carrabba's - The Original on Kirby
3115 Kirby Dr.
Houston, TX 77098

QUESTIONS

Kim Culpepper
Sales Executive
kim.culpepper@myriad.com
(713) 298-8408

RSVP

Please RSVP by
June 9, 2026

TO REGISTER

Click [Here](#) or scan
the QR code below



This event is not open to the general public. If you were not the original recipient of this invitation, please contact a GeneSight representative with your request to attend.

The GeneSight® Psychotropic test is a genetics-based decision support tool that analyzes clinically important genetic variations that may affect your patient's outcomes with certain psychiatric medications. Use of the GeneSight Psychotropic test can help inform your medication selection. The results show which medications may require dose adjustments, may be less likely to work, or may have an increased risk of side effects based on your patient's genetic makeup. The clinical validity, clinical utility, and economic utility of the GeneSight Psychotropic test have been evaluated in seven published, peer-reviewed clinical trials. In the GUIDED study, patients in the GeneSight arm experienced an 11% relative improvement in symptoms, a 30% relative improvement in response rates, and a 50% relative improvement in remission rates compared to treatment as usual at week 8.



6960 Cintas Blvd
Mason, OH 45040
866.260.2394



www.genesight.com